164 related articles for article (PubMed ID: 24089157)
1. High prevalence of secondary hyperparathyroidism in chronic kidney disease patients on dialysis in Argentina.
Douthat WG; Castellano M; Berenguer L; Guzmán MA; de Arteaga J; Chiurchiu CR; Massari PU; Garay G; Capra R; de La Fuente JL
Nefrologia; 2013; 33(5):657-66. PubMed ID: 24089157
[TBL] [Abstract][Full Text] [Related]
2. A long-term, multicenter study of the efficacy and safety of paricalcitol in end-stage renal disease.
Lindberg J; Martin KJ; González EA; Acchiardo SR; Valdin JR; Soltanek C
Clin Nephrol; 2001 Oct; 56(4):315-23. PubMed ID: 11680662
[TBL] [Abstract][Full Text] [Related]
3. Pulse intravenous calcitriol therapy of secondary hyperparathyroidism in peritoneal dialysis patients.
Wadhwa NK; Suh H; Howell N; Cabralda T; Sokunbi D; Solomon M
Adv Perit Dial; 1993; 9():260-3. PubMed ID: 8105939
[TBL] [Abstract][Full Text] [Related]
4. Frequent recurrence of secondary hyperparathyroidism after pulse oral calcitriol withdrawal in PD patients.
Bajo MA; Selgas R; Possante C; Aguilera A; Sánchez C; Diaz C; de Alvaro F; Martinez ME
Adv Perit Dial; 1997; 13():239-43. PubMed ID: 9360690
[TBL] [Abstract][Full Text] [Related]
5. Paricalcitol in dialysis patients with calcitriol-resistant secondary hyperparathyroidism.
Llach F; Yudd M
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S45-50. PubMed ID: 11689387
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and side effects of intermittent intravenous and oral doxercalciferol (1alpha-hydroxyvitamin D(2)) in dialysis patients with secondary hyperparathyroidism: a sequential comparison.
Maung HM; Elangovan L; Frazão JM; Bower JD; Kelley BJ; Acchiardo SR; Rodriguez HJ; Norris KC; Sigala JF; Rutkowski M; Robertson JA; Goodman WG; Levine BS; Chesney RW; Mazess RB; Kyllo DM; Douglass LL; Bishop CW; Coburn JW
Am J Kidney Dis; 2001 Mar; 37(3):532-43. PubMed ID: 11228177
[TBL] [Abstract][Full Text] [Related]
7. RenaGel efficacy in severe secondary hyperparathyroidism.
Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
[TBL] [Abstract][Full Text] [Related]
8. The renal dietitian's role in managing hyperphosphatemia and secondary hyperparathyroidism in dialysis patients: a national survey.
Martin CJ; Reams SM
J Ren Nutr; 2003 Apr; 13(2):133-6. PubMed ID: 12671837
[TBL] [Abstract][Full Text] [Related]
9. Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2.
Llach F; Keshav G; Goldblat MV; Lindberg JS; Sadler R; Delmez J; Arruda J; Lau A; Slatopolsky E
Am J Kidney Dis; 1998 Oct; 32(2 Suppl 2):S48-54. PubMed ID: 9808143
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of small doses of calcitriol in hemodialysis patients with moderate secondary hyperparathyroidism.
Vlassopoulos D; Noussias C; Revenas K; Hadjilouka-Mantaka A; Arvanitis D; Tzortzis G; Hadjiconstantinou V
Ren Fail; 1999 Mar; 21(2):199-207. PubMed ID: 10088180
[TBL] [Abstract][Full Text] [Related]
11. Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure. European Study Group on Vitamin D in Children with Renal Failure.
Ardissino G; Schmitt CP; Testa S; Claris-Appiani A; Mehls O
Pediatr Nephrol; 2000 Jul; 14(7):664-8. PubMed ID: 10912539
[TBL] [Abstract][Full Text] [Related]
12. Limitations of pulse oral calcitriol therapy in continuous ambulatory peritoneal dialysis patients.
Bechtel U; Mücke C; Feucht HE; Schiffl H; Sitter T; Held E
Am J Kidney Dis; 1995 Feb; 25(2):291-6. PubMed ID: 7847357
[TBL] [Abstract][Full Text] [Related]
13. Vitamin D analogues for the management of secondary hyperparathyroidism.
Martin KJ; González EA
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
[TBL] [Abstract][Full Text] [Related]
14. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study.
Gallieni M; Cucciniello E; D'Amaro E; Fatuzzo P; Gaggiotti A; Maringhini S; Rotolo U; Brancaccio D;
J Nephrol; 2002; 15(2):165-70. PubMed ID: 12018633
[TBL] [Abstract][Full Text] [Related]
15. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism.
Park CW; Oh YS; Shin YS; Kim CM; Kim YS; Kim SY; Choi EJ; Chang YS; Bang BK
Am J Kidney Dis; 1999 Jan; 33(1):73-81. PubMed ID: 9915270
[TBL] [Abstract][Full Text] [Related]
16. [Alkaline phosphatase of bone origin in hemodialyzed patients. 110 assays].
Ureña P; Prieur P; Pétrover M
Presse Med; 1996 Oct; 25(29):1320-5. PubMed ID: 8942941
[TBL] [Abstract][Full Text] [Related]
17. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy.
Goodman WG; Ramirez JA; Belin TR; Chon Y; Gales B; Segre GV; Salusky IB
Kidney Int; 1994 Oct; 46(4):1160-6. PubMed ID: 7861712
[TBL] [Abstract][Full Text] [Related]
18. Normocalcemic hyperparathyroidism associated with relatively low 1:25 vitamin D levels post-renal transplant can be successfully treated with oral calcitriol.
Lobo PI; Cortez MS; Stevenson W; Pruett TL
Clin Transplant; 1995 Aug; 9(4):277-81. PubMed ID: 7579733
[TBL] [Abstract][Full Text] [Related]
19. Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism.
Frazão JM; Elangovan L; Maung HM; Chesney RW; Acchiardo SR; Bower JD; Kelley BJ; Rodriguez HJ; Norris KC; Robertson JA; Levine BS; Goodman WG; Gentile D; Mazess RB; Kyllo DM; Douglass LL; Bishop CW; Coburn JW
Am J Kidney Dis; 2000 Sep; 36(3):550-61. PubMed ID: 10977787
[TBL] [Abstract][Full Text] [Related]
20. [Calcitriol dose optimization in the treatment of secondary hyperparathyroidism during dialysis. Results at 6 months].
Rodríguez García M; Fernández Martín JL; Ruiz de Castañeda J; Hervás Sánchez J; Cannata Andía JB;
Nefrologia; 2002; 22(4):370-6. PubMed ID: 12369129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
